Our Identity
We are disrupters
Our innovative approach redefines drug development. By starting with FDA-approved parent drugs that are already well-understood, we reduce downstream development risk while achieving a high level of effectiveness. We combine these parent drugs with specific cannabinoids at a molecular level creating novel molecules that outperform traditional therapies. Our new molecules demonstrate superior properties: improved efficacy, delivery, and safety when compared to the parent drug individually, the cannabinoid individually, or any conventional combination therapy using the parent drug and the cannabinoid.
Our Patents
Granted
US 11877988
US 12121584
US 17622319
AU 2020366257
